On paper, things should be looking up for Japan’s pharmaceutical wholesalers. Industry expectations are mounting that the average gap between NHI and market prices will narrow further in FY2026 from the previous year’s record low of 4.8%.A shrinking gap should…
HOME > TOP STORIES
TOP STORIES
-
COMMENTARY Impact on Japanese Pharmaceutical Companies Unavoidable: TPP Negotiations
October 19, 2011
-
BUSINESS Takeda Initiates PIII Clinical Trials for Antidiabetic TAK-875 in US, Europe
October 19, 2011
-
ORGANIZATION Keizai Doyukai’s Hasegawa Appointed National Strategy Council’s Private Sector Member, Vows “All-Out Effort
October 19, 2011
-
REGULATORY PMDA Presents Warnings on Website to Prevent Mistaken Use of 3 Taxane Drugs
October 19, 2011
-
BUSINESS MTPC Aims at Sales of ¥500 Bil. in FY2015
October 18, 2011
-
REGULATORY Council to Set Up Committee to Discuss Creation of “Drug Discovery Support Organization”
October 18, 2011
-
REGULATORY MHLW to Survey, Consider Measures for Clinical Trials in Coping with Earthquakes
October 17, 2011
-
REGULATORY Vice Minister Tsuji Supports Continuation of Premium for New Drug Development
October 17, 2011
-
BUSINESS Shionogi Completes TOB for C&O Pharmaceutical Technology of China
October 14, 2011
-
BUSINESS Doctor Survey for Information Provision Through Tablet Computers: Otsuka, Takeda Lead HP, GP
October 13, 2011
-
REGULATORY Avastin Approved for Treatment of Breast Cancer in Combination with Paclitaxel
October 13, 2011
-
ORGANIZATION 17 Additional Products Eligible for PDSC Development Subsidies
October 12, 2011
-
BUSINESS Takeda Bio Initiates P1/2 Trial of Malignant Lymphoma Treatment in Japan
October 12, 2011
-
ORGANIZATION Industry to Seek Additional Data for Full Introduction of Premium for New Drug Development: Mr Negi
October 11, 2011
-
BUSINESS Takeda Discontinues Development of Insomnia Drug Ramelteon in Europe
October 11, 2011
-
BUSINESS Takeda to Offer Information on Actos for Prescribing Doctors
October 7, 2011
-
BUSINESS Mediceo Aiming for 20% Market Share in Hokkaido within 3 Years: President Watanabe
October 7, 2011
-
BUSINESS Aiming for 6% Yearly Growth by Rivaroxaban Launching: Bayer AG
October 6, 2011
-
REGULATORY Number of Pharmacies Qualifying for Premiums for GE Drug Dispensing Systems Down in 2010
October 6, 2011
-
BUSINESS Takeda President Hasegawa Says Innovation Will Take Place in Developing Countries
October 5, 2011
ページ
Japan is set to add 16 new drugs to its NHI reimbursement price list on November 13, including a subcutaneous…
Japan will trim the NHI price of Eli Lilly Japan’s Alzheimer’s treatment Kisunla (donanemab) by 3.93% under the cost-effectiveness assessment…
Tariffs have been a defining feature of US trade policy under President Donald Trump’s second administration. Since Trump unveiled his “reciprocal” tariff policy in April 2025, the landscape has shifted repeatedly.In February 2026, the US Supreme Court invalidated tariffs imposed…
As Japan’s budget season draws near, the Ministry of Finance (MOF) has renewed its push for a full-scale “off-year” drug…
Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…